{"schema_version":"secwatch.filing_event.v1","accession":"0001724521-24-000050","form_type":"8-K","ticker":"RCUS","cik":"0001724521","company_name":"Arcus Biosciences, Inc.","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.260682+00:00","generated_at":"2026-06-05T22:11:45.191530+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcus Q4 net loss $81M; cash to $1.2B after Gilead; streamlines TIGIT program; casdatifan shows promise","bullets":["Net loss of $81M in Q4 2023 ($307M full year); revenue $31M Q4 2023 vs $34M Q4 2022.","Pro forma cash $1.2B after $320M equity investment from Gilead in Jan 2024; funding into 2027.","Discontinued ARC-10 Phase 3 in PD-L1-high NSCLC; accelerating STAR-121; planning STAR-131 in perioperative NSCLC.","Casdatifan (HIF-2a) Phase 1 data: 20 mg dose achieved similar EPO suppression as 120 mg belzutifan; no DLTs.","Quemliclustat in pancreatic cancer: median OS 15.7 months in pooled ARC-8 analysis; Phase 3 planned early 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001724521-24-000050","json":"https://secwatch.observer/filing/0001724521-24-000050.json","markdown":"https://secwatch.observer/filing/0001724521-24-000050.md","text":"https://secwatch.observer/filing/0001724521-24-000050.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000050/0001724521-24-000050-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000050/rcus-20240221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T22:11:45.191530+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4f42f0d0a4a223c48c91dd838111f9c951495fa0","claim":"Arcus Biosciences, Inc. reported financial results for the three months and full year ended December 31, 2023.","evidence_excerpt":"On February 21, 2024, Arcus Biosciences, Inc. issued a press release announcing its financial results for the three months and full year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452124000050/0001724521-24-000050-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}